PEPTIDE CORPUS
Start free
Peptides Conditions Goals Protocols Glossary Articles Evidence Tools Shop
Sign in Start free

Protocol

Running a growth-hormone protocol

What the record holds about the schedule for the GH secretagogues and the hormone itself: the interval, the half-life, and whether anything accumulates.

Last updated

15compounds in this class
12with a half-life on file
13with a schedule on file
11curves drawn

12 of 15 hold a half-life measurement. A curve needs that and a schedule, which is why 11 lines are drawn below and 4 members appear in the table with no line at all.

This is the best-covered corner of the corpus for pharmacokinetics and the most interesting one to chart, because almost nothing here accumulates. Fifteen compounds, ten with a half-life on file, and exactly one of them holds enough of a dose over its interval to build a plateau. The rest spike and clear, which is the shape the axis is supposed to have — and it is the opposite of what a weekly GLP-1 does.

The schedule on file

Read the last column first. Four kinds of thing get printed as a dose in this category and they are not the same kind of fact: an approved label, a trial protocol, a figure the community circulates, and arithmetic done on an animal study. What each chip means.

Every member of this class, including the ones no curve could be drawn for.
CompoundSchedule on fileHalf-lifeAccumulationWhere the schedule comes from
CJC-1295 DACcurve twice a week2-4 mg weekly 6.9 d5.8 d to 1.2 wkhuman, SC 3.39×the steady peak is 3.39 times the first circulatedA phase 1 single-dose study is on file; the 1 to 2 mg weekly schedule is not from it.
hGHcurve daily0.5-4 IU daily 3.4 hhuman, SC noneeach dose has cleared before the next arrives labelSomatropin is a licensed medicine and its schedules come from product labels. No somatropin label is on file in this corpus, so the badge is the kind of schedule this is, not a document we hold.
GHRP-2curve daily100-300 mcg daily 33 minhuman, route not stated noneeach dose has cleared before the next arrives circulated
Tesamorelincurve daily1-2 mg daily 10 min8 min to 11 minhuman, SC noneeach dose has cleared before the next arrives label EGRIFTA WR
Sermorelincurve daily200-500 mcg daily 4 minhuman, IV noneeach dose has cleared before the next arrives labelGeref was an approved product and the schedule is its labelled one. It was withdrawn and no sermorelin label is published by DailyMed or openFDA any more, so there is nothing on file here to link.
IGF-1curve twice dailySC: 40-120 mcg/kg BID (escalating); SC: 10-20 mg/day; IV: 1-4 mg/kg single dose 6 hhuman, SC 1.33×the steady peak is 1.33 times the first circulatedMecasermin is licensed and labelled; the schedule on file here is not from that label.
GHRP-6curve twice daily100-300 mcg daily 2.5 hhuman, IV noneeach dose has cleared before the next arrives circulated
GHRH (Growth Hormone-Releasing Hormone)curve twice dailySC: 10 mcg/kg nightly; 0.5-1.0 mg BID; 2 mg QD; IV: 1 mcg/kg q3h; 0.03-3.0 mcg/kg 8 minhuman, SC noneeach dose has cleared before the next arrives trialA diagnostic infusion, not a regimen.
Ipamorelincurve 7-21x a week100-300 mcg daily 2 hhuman, IV infusion noneeach dose has cleared before the next arrives circulated
Hexarelincurve 14-21x a weekIV: 0.5-2.0 mcg/kg single dose; SC: 1.5 mcg/kg 2-3x/day; Intranasal: 40-60 mcg/kg TID 1.1 h57 min to 1.2 hrat, SC noneeach dose has cleared before the next arrives circulated
CJC-1295 no-DACcurve 7-21x a week100-300 mcg daily 7 minhuman, IV noneeach dose has cleared before the next arrives circulated
Ghrelinsingle dose no schedule on fileIV bolus: 1-5 µg/kg; IV infusion: 0.1 µg/kg/min or 30 pmol/kg/min 11 minhuman, IV —needs a half-life and an interval from the same record trialAn infusion used in physiology studies.
IGF-1 LR3schedule only daily20-80 mcg daily not on file —needs a half-life and an interval from the same record circulated
MK-677schedule only daily10-25 mg daily not on file —needs a half-life and an interval from the same record trial25 mg once daily is the schedule the published trials used.
GHRP-1schedule only no schedule on fileIV: 1 mcg/kg bolus; IV: 0.05-2.5 mcg/kg infusion; SC: single injection (NCT00381602) not on file —needs a half-life and an interval from the same record circulated

What the schedule does over time

Each line is one compound's amount in the body as a percentage of its own peak, from the first dose onwards. Compounds share a chart only when they share a dosing interval, because that is the only comparison the shape supports. 2 compounds build between doses; the multiplier is in the table above.

One dose every 3.5 d — 1 compound, four doses shown, each normalised to its own peak.
1 compounds on one time axis, each normalised to its own peak0%25%50%75%100%0 min3.5 d1 wk1.5 wk2 wkpeaktime from the first doseCJC-1295 DAC
  1. CJC-1295 DAC half-life 6.9 d, builds to 3.39× the record says 1 to 2 times a week; the fastest is drawn
One dose every 24 h — 4 compounds, four doses shown, each normalised to its own peak.
4 compounds on one time axis, each normalised to its own peak0%25%50%75%100%0 min24 h2 d3 d4 dpeaktime from the first dosehGHGHRP-2TesamorelinSermorelin
  1. hGH half-life 3.4 h, no accumulation
  2. GHRP-2 half-life 33 min, no accumulation
  3. Tesamorelin half-life 10 min, no accumulation
  4. Sermorelin half-life 4 min, no accumulation
One dose every 12 h — 3 compounds, four doses shown, each normalised to its own peak.
3 compounds on one time axis, each normalised to its own peak0%25%50%75%100%0 min12 h24 h36 h2 dpeaktime from the first doseIGF-1GHRP-6GHRH (Growth Hormone-Releasing Hormone)
  1. IGF-1 half-life 6 h, builds to 1.33×
  2. GHRP-6 half-life 2.5 h, no accumulation
  3. GHRH (Growth Hormone-Releasing Hormone) half-life 8 min, no accumulation
One dose every 8 h — 3 compounds, four doses shown, each normalised to its own peak.
3 compounds on one time axis, each normalised to its own peak0%25%50%75%100%0 min8 h16 h24 h32 hpeaktime from the first doseIpamorelinHexarelinCJC-1295 no-DAC
  1. Ipamorelin half-life 2 h, no accumulation the record says 7 to 21 times a week; the fastest is drawn
  2. Hexarelin half-life 1.1 h, no accumulation the record says 14 to 21 times a week; the fastest is drawn
  3. CJC-1295 no-DAC half-life 7 min, no accumulation the record says 7 to 21 times a week; the fastest is drawn

What the curves do not model

The half-life was measured by a different route than the one it is given by. Sermorelin, CJC-1295 no-DAC have intravenous half-lives on file and are not administered that way. That does not make the number useless — it makes it a lower bound. Absorption from the injection site keeps supplying the blood after an intravenous bolus would have cleared, so the real curve is flatter and lasts longer than the one drawn here. It is never shorter.

One half-life was measured in an animal. Hexarelin (rat). Small mammals clear peptides faster than people do, so that curve is the fastest plausible shape rather than the expected one. The species is on every row above and on the compound's own record.

The rise is not modelled. No absorption rate constant is on file for anything here, so every dose appears at full height the instant it is given. A real subcutaneous injection takes hours to peak. The decay is measured; the vertical line at each dose is a placeholder for a shape there is nothing to draw.

The axis is percent of each compound's own peak, and it is not a blood level. No volume of distribution is on file for anything on this page, so no curve here can carry a concentration. Two lines both at 50% are two compounds each at half of their own maximum — not two equal amounts of anything, and not a comparison of potency.

Combining within this class

Only the pairings somebody wrote a rule for are listed. A pairing that is absent is absent from our records, which is a statement about the records and not about safety. The full grid, including every pairing with nothing on record, is in the stack checker.

GHRH analog with ghrelin mimetic (GHS-R)works together in theory

Different receptors on the same axis: a GHRH analog raises pulse amplitude while a ghrelin mimetic raises pulse frequency and is expected to suppress somatostatin. Pairing one of each is the standard secretagogue protocol. No study has administered the combination and measured the result, and the somatostatin step is inferred from the class rather than measured for these compounds.

class rule — the textbook GH-pulse model, argued rather than demonstrated.

Two GHRH analogs togethercaution

Two GHRH analogs drive the same receptor. The second adds receptor load without a new mechanism, and total GH/IGF-1 exposure rises with no established ceiling.

class rule — receptor duplication.

Two ghrelin mimetic (GHS-R)s togethercaution

Two ghrelin mimetics drive the same GHS-R receptor. This includes MK-677 alongside an injectable GHRP — oral route does not change the receptor.

class rule — receptor duplication.

direct GH/IGF-1 with GHRH analogcaution

Exogenous GH or IGF-1 on top of a secretagogue stacks the axis from two directions; total IGF-1 exposure is the concern and it is unmonitored outside a trial.

class rule — additive axis load.

direct GH/IGF-1 with ghrelin mimetic (GHS-R)caution

Exogenous GH or IGF-1 on top of a secretagogue stacks the axis from two directions; total IGF-1 exposure is the concern and it is unmonitored outside a trial.

class rule — additive axis load.

Two direct GH/IGF-1s togethercaution

GH and IGF-1 together, or either doubled, is the axis dosed twice.

class rule — additive axis load.

CJC-1295 no-DAC with Ipamorelinworks together in theory

The canonical GHRH + ghrelin-mimetic pairing, routinely combined and sold pre-blended. Its rationale is that the two act at different receptors on one axis; the somatostatin-suppression step that argument rests on has not been measured for ipamorelin specifically, and no study has given the two together. Same-syringe compatibility is a separate question the syringe planner answers.

curated pair — the ghrh × ghrp class rule on its best-known instance; mechanism argued, combination untested.

What the evidence says, separately

This page is about the schedule. It says nothing about whether any of it works — that is graded row by row against a named condition, and it lives on the goal pages, each of which opens with how many compounds were checked before it says which earned a row.

What this page does not say

It reports the schedules on file and what the measured half-lives imply about them. It does not recommend a compound, a dose, an interval or a combination, and a schedule appearing here is a record that somebody publishes it rather than a reason to run it. Three of the four source classes are not approvals of anything.

Lay this out as a week

The planner takes a list of compounds and turns it into administration days, with the vial maths and the same-syringe question answered per pairing.

Browse by protocol